Re: A Leading Indicator Of Success: Failure And Risk In Biotechnology
in response to
by
posted on
Jul 08, 2013 08:44PM
Edit this title from the Fast Facts Section
Hit pieces and pump pieces both have a lot of misleading statements, recall the continued line about Al Mann "buying" 48 zillion shares, when we all knew he exchanged debt which could have well become worthless had he not helped by extending credit, etc.
The continued comparison to Exubra and other drugs is what bothers me; I'm convinced this one will be wildly successful if approved, but approval is just not assured. There are smart people out there that have done some research into the company that think it more likely than not it will not pass FDA muster. Most of us here disagree. It's what makes a horse race.
But these SA, MF, etc. articles, they are, for the most part, misleading, at least we can see how they are misleading, hopefully from both the pro and the con side!